Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. is a medical diagnostics company based in Acton, Massachusetts, founded in 2015. The company focuses on developing innovative diagnostic technologies that enhance patient outcomes through rapid and cost-efficient near-patient testing for triage, diagnosis, and disease monitoring. The core offering is the Symphony platform, an automated diagnostic system that combines a fluorescence immuno-analyzer with a single-use test cartridge. This system utilizes advanced microfluidics and nanotechnology to perform sensitive biomarker detection. The Symphony platform operates in a “sample-to-result” format, simplifying the testing process and making it suitable for hospitals, long-term acute care facilities, and clinics that require timely diagnostics. Bluejay Diagnostics also offers the ALLEREYE test for diagnosing allergic conjunctivitis and is developing additional tests for monitoring interleukin-6 levels, myocardial infarction, and congestive heart failure. The company aims to provide healthcare providers with accessible diagnostic solutions that improve decision-making in acute care settings. Bluejay Diagnostics is publicly traded on NASDAQ under the ticker symbol BJDX.

• Employees 7
• Founded 2015
• Annual Revenue $216000
• Total Funding $36443608